UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000009568 |
|---|---|
| Receipt number | R000011227 |
| Scientific Title | A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressing |
| Date of disclosure of the study information | 2012/12/21 |
| Last modified on | 2017/06/10 18:47:23 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2012/12/17 21:48:40 | ||
| 2 | Update | 2012/12/17 21:49:34 | Public title |
|
| 3 | Update | 2012/12/17 21:50:09 | Condition Narrative objectives1 |
|
| 4 | Update | 2015/06/18 10:45:49 | Key inclusion criteria Key inclusion criteria |
|
| 5 | Update | 2015/06/18 10:48:14 | TEL Last name of contact person Last name of contact person Address Address |
|
| 6 | Update | 2017/06/10 18:46:15 | Name of primary person or sponsor Organization |
|
| 7 | Update | 2017/06/10 18:47:23 | Recruitment status |
